D-0328-2022 Class II Terminated
FDA drug recall D-0328-2022 was initiated by Perrigo Company PLC on Jul 27, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing. The recall status is terminated (terminated Nov 8, 2022). Affected quantity: 55,032 units.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 12, 2022
- Initiation Date
- Jul 27, 2021
- Termination Date
- Nov 8, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 55,032 units
Product description
EQUALINE aller-ease fexofenadine hydrochloride tablets, 180 mg, 24 HR, packaged as a) 15 count bottle, NDC 41163-571-22, UPC 0 41163 48067 4; b) 70 tablets per bottle, NDC 41163-571-01, UPC 0 41163 49847 1; Made in the Czech Republic, Distributed by: UNFI Providence, RI 02908.
Reason for recall
Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.
Distribution pattern
Nationwide in the USA
Code information
Lot # a)0HE2530 Exp 12/31/2021, 0KE2980 EXP 02/28/2022 b)0FR0461 Exp 2/28/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0328-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026